HC Wainwright upgraded Kyverna Therapeutics Inc. KYTX, citing three upcoming data sets through mid-2025. In its first quarter 2025 earnings released, the company highlighted: Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS). The trial is on track for topline data and a biologics license application (BLA) filing is
The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s ALDX resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA “failed to demonstrate efficacy in adequate and well-controlled studies in treating ocular symptoms associated
BofA Securities analyst Lawson Winder discussed the performance of gold price last week and where it is headed. Gold prices have exceeded the analyst’s long-term target of $3,000 per ounce, with the analyst suggesting a potential rise to $3,500 if investment demand grows by 10%. China’s insurance sector could allocate up to 1% of its
Wheaton Precious Metals WPM has outperformed the market over the past 5 years by 2.73% on an annualized basis producing an average annual return of 17.03%. Currently, Wheaton Precious Metals has a market capitalization of $30.38 billion. Buying $1000 In WPM: If an investor had bought $1000 of WPM stock 5 years ago, it would